$92.38
0.00% yesterday
Nasdaq, Dec 12, 10:13 pm CET
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Gilead Sciences Stock price

$92.38
-1.97 2.09% 1M
+28.04 43.58% 6M
+11.37 14.04% YTD
+11.56 14.30% 1Y
+21.77 30.83% 3Y
+24.75 36.60% 5Y
-11.75 11.28% 10Y
Nasdaq, Closing price Thu, Dec 12 2024
+0.00 0.00%
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Key metrics

Market capitalization $115.13b
Enterprise Value $131.60b
P/E (TTM) P/E ratio 1,041.49
EV/FCF (TTM) EV/FCF 13.95
EV/Sales (TTM) EV/Sales 4.65
P/S ratio (TTM) P/S ratio 4.07
P/B ratio (TTM) P/B ratio 6.23
Dividend yield 3.33%
Last dividend (FY24) $3.08
Revenue growth (TTM) Revenue growth 3.72%
Revenue (TTM) Revenue $28.27b
EBIT (operating result TTM) EBIT $10.59b
Free Cash Flow (TTM) Free Cash Flow $9.43b
Cash position $6.70b
EPS (TTM) EPS $0.09
P/E forward 480.08
P/S forward 4.07
EV/Sales forward 4.65
Short interest 1.88%
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Analyst Opinions

32 Analysts have issued a Gilead Sciences forecast:

18x Buy
56%
14x Hold
44%

Analyst Opinions

32 Analysts have issued a Gilead Sciences forecast:

Buy
56%
Hold
44%

Financial data from Gilead Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
28,273 28,273
4% 4%
100%
- Direct Costs 6,230 6,230
16% 16%
22%
22,043 22,043
1% 1%
78%
- Selling and Administrative Expenses 2,976 2,976
25% 25%
11%
- Research and Development Expense 5,718 5,718
2% 2%
20%
13,349 13,349
11% 11%
47%
- Depreciation and Amortization 2,762 2,762
9% 9%
10%
EBIT (Operating Income) EBIT 10,587 10,587
11% 11%
37%
Net Profit 126 126
98% 98%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Neutral
Reuters
about 9 hours ago
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
Neutral
Business Wire
about 10 hours ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of ...
Neutral
Business Wire
3 days ago
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follow-up of m...
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 18,000
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today